neuroClues, a France- and Belgium-based MedTech startup has completed a €10 million Series A round, as well as non-dilutive funding. This makes its total funding €25 million. The funding round was led by Teampact Ventures, White Fund and the EIC Fund in addition to existing investors and industry leaders.
The startup specializes in the early detection of neurological disorders, much earlier than you typically would. Its technology enables clinicians to detect indications of illness years before becoming overtly symptomatic. CEO Antoine Pouppez said the funding validates both its technology and team able to execute. The company already obtained CE certification in record time and initiate early commercial use within a couple of weeks, he said.
Founded in 2020, neuroClues develops a small medical device that is non-invasive and tracks and studies eye movements. By analyzing these movements, the system generates clean, repeatable data that can assist doctors with diagnosing and monitoring brain disorders.
Neurological diseases are increasing globally and can be difficult to diagnose. The company says about one in three people may be affected by these conditions, and diseases such as Parkinson’s are projected to increase sharply in the years ahead. Many people are still misdiagnosed and the correct diagnosis is often only made once serious and irreversible brain damage has taken place.
Doctors mainly rely on simple physical tests and observation, which offer no quantifiable output. Advanced tools like imaging can be expensive and aren’t always available, and they may not detect problems at early stages.
The neuroClues device employs high-speed infrared imaging to track eye movements as patients complete simple tasks. Its software then translates that information into actionable clinical insights. The system is user friendly, integrates with typical clinical workflows and returns results in minutes. It also supports remote analysis.
The aim is to substitute subjective tests for clear and data-structured assessment. The goal is to help physicians more accurately diagnose conditions including Parkinson’s, Alzheimer’s and brain injuries as data becomes available.
In January 2025, CE certification was issued for the device. Since then, over 30 units have been deployed in multiple European countries to hospitals, clinics and research center. Healthcare professionals keep showing interest.
The company is also engaged in major clinical studies, including projects that seek to create a data base of eye movement biomarkers from 25,000 participants. This should aid in emphasising accurate and early detection.
To facilitate the expansion, neuroClues has bolstered its leadership team and is scaling up its commercial operations throughout Europe. It has also enabled a limited investment opportunity for retail investors via a European platform to broaden participation in its funding round.
Business Outstanders brings you sharp insights on tech, business, entrepreneurship, law, crypto, and more. We uncover what’s next. Stay updated, sign up for our newsletter and be part of the future!
